Artificial intelligence specialist Owkin has added another piece to its medical research portfolio with the launch of ...

Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data access and advance medical ...

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective ...

Owkin has announced a partnership with AstraZeneca to create an AI gBRCA pre-screening solution designed to identify ...

Oncology researcher Pierce works at Owkin, a Paris-based biotech with a modest goal for AI, he says with a laugh: To double the chances of drug development success from the industry standard of ...

Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug ...

France’s Servier has become the latest pharma group to tap into an artificial intelligence platform for drug discovery, development, and diagnostics developed by Franco-US biotech Owkin.

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...

Owkin’s solution is to bring academic and pharmaceutical industry researchers together in a federated research environment. Here, the company’s proprietary infrastructure and artificial ...

En’owkin, practiced as a rules-to-order technique, solicits voluntary deep collaboration. As such, En’owkin is engaged in by the community as a customary procedure in order to insure that the ...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class ...